ENTRY       D10181                      Drug
NAME        Umeclidinium bromide (JAN/USAN);
            Incruse ellipta (TN)
PRODUCT     INCRUSE ELLIPTA (GlaxoSmithKline LLC)
FORMULA     C29H34NO2. Br
EXACT_MASS  507.1773
MOL_WEIGHT  508.4898
CLASS       Neuropsychiatric agent
             DG01491  Muscarinic cholinergic receptor antagonist
            Metabolizing enzyme substrate
             DG01644  CYP2D6 substrate
REMARK      Therapeutic category: 2259
            ATC code: R03BB07
            Chemical structure group: DG01253
            Product (DG01253): D10181<JP/US>
            Product (mixture): D10533<JP/US> D11035<JP/US>
EFFICACY    Bronchodilator, Muscarinic acetylcholine receptor antagonist
  DISEASE   Chronic obstructive pulmonary disease [DS:H01714]
COMMENT     Quaternary ammonium compound
TARGET      CHRM [HSA:1128 1129 1131 1132 1133] [KO:K04129 K04130 K04131 K04132 K04133]
  PATHWAY   hsa04020(1128+1129+1131+1133)  Calcium signaling pathway
            hsa04080(1128+1129+1131+1132+1133)  Neuroactive ligand-receptor interaction
            hsa04725(1128+1129+1131+1132+1133)  Cholinergic synapse
METABOLISM  Enzyme: CYP2D6 [HSA:1565]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             R RESPIRATORY SYSTEM
              R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
               R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
                R03BB Anticholinergics
                 R03BB07 Umeclidinium bromide
                  D10181  Umeclidinium bromide (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Respiratory Tract/Pulmonary Agents
              Bronchodilators, Anticholinergic
               Umeclidinium
                D10181  Umeclidinium bromide (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              22  Respiratory organ agents
               225  Bronchodilators
                2259  Others
                 D10181  Umeclidinium bromide (JAN/USAN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01491  Muscarinic cholinergic receptor antagonist
               DG01253  Umeclidinium
                D10181  Umeclidinium bromide
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG01253  Umeclidinium
                D10181  Umeclidinium bromide
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Acetylcholine (muscarinic)
                CHRM
                 D10181  Umeclidinium bromide (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10181
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10181
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10181
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01491  Muscarinic cholinergic receptor antagonist
               DG01253  Umeclidinium
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG01253  Umeclidinium
DBLINKS     CAS: 869113-09-7
            PubChem: 135626899
            ChEBI: 79040
            LigandBox: D10181
ATOM        33
            1   C1x C    26.1100  -23.1000
            2   C1z C    24.8500  -22.4000
            3   C1x C    26.1100  -24.6400
            4   C1x C    23.5900  -23.1000
            5   C1x C    25.2700  -23.7300
            6   N2y N    24.8500  -25.3400 #+
            7   C1x C    23.5900  -24.5700
            8   C1x C    24.4300  -23.9400
            9   C1b C    24.8500  -26.7400
            10  C1b C    23.6600  -27.4400
            11  O2a O    22.4000  -26.7400
            12  C1b C    21.2100  -27.4400
            13  C8y C    20.0200  -26.7400
            14  C8x C    20.0200  -25.3400
            15  C8x C    18.8300  -24.6400
            16  C8x C    17.5700  -25.3400
            17  C8x C    17.5700  -26.7400
            18  C8x C    18.8300  -27.4400
            19  C1d C    24.8500  -21.0000
            20  C8y C    26.1100  -20.3000
            21  C8y C    23.6600  -20.3000
            22  O1a O    26.1100  -21.7000
            23  C8x C    27.3000  -21.0000
            24  C8x C    28.4900  -20.3000
            25  C8x C    28.4900  -18.9000
            26  C8x C    27.3000  -18.2000
            27  C8x C    26.1100  -18.9000
            28  C8x C    23.6600  -18.9000
            29  C8x C    22.4000  -18.2000
            30  C8x C    21.2100  -18.9000
            31  C8x C    21.2100  -20.3000
            32  C8x C    22.4000  -21.0000
            33  X   Br   28.1400  -26.8100 #-
BOND        36
            1     1   2 1
            2     1   3 1
            3     2   4 1
            4     2   5 1
            5     3   6 1
            6     4   7 1
            7     5   8 1
            8     6   7 1
            9     6   8 1
            10    6   9 1
            11    9  10 1
            12   10  11 1
            13   11  12 1
            14   12  13 1
            15   13  14 2
            16   14  15 1
            17   15  16 2
            18   16  17 1
            19   17  18 2
            20   13  18 1
            21    2  19 1
            22   19  20 1
            23   19  21 1
            24   19  22 1
            25   20  23 2
            26   23  24 1
            27   24  25 2
            28   25  26 1
            29   26  27 2
            30   20  27 1
            31   21  28 2
            32   28  29 1
            33   29  30 2
            34   30  31 1
            35   31  32 2
            36   21  32 1
///
